<DOC>
	<DOCNO>NCT00002610</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . It yet know therapy regimen effective treat patient kidney tumor . PURPOSE : Phase III trial compare effectiveness chemotherapy without radiation therapy , surgery , and/or peripheral stem cell bone marrow transplantation treat young patient kidney tumor .</brief_summary>
	<brief_title>Chemotherapy With Without Surgery , Radiation Therapy , Stem Cell Transplantation Treating Young Patients With Kidney Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine 2-year second-event-free survival vincristine ( VCR ) dactinomycin ( DACT ) without doxorubicin ( DOX ) , depend site relapse presence microscopic residual disease , child relapse Wilm 's tumor previously treat nephrectomy alone initial therapy . - Determine whether 2-year second-event-free survival intensive doxorubicin , etoposide ( VP-16 ) , cyclophosphamide ( CTX ) , carboplatin ( CBDCA ) plus radiotherapy residual disease least 40 % high patient relapse Wilm 's tumor previously treat Regimen EE-4A initial therapy without loss heterozygosity chromosomes 16q 1p increase DNA content tumor cell similarly treat patient loss heterozygosity chromosome 16q 1p increase DNA content tumor cell . - Determine whether 4-year post-relapse survival intensive VP-16 , CTX , CBDCA least 40 % high patient relapse Wilm 's tumor previously treat Regimen DD-4A initial therapy without loss heterozygosity chromosomes 16q 1p increase DNA content tumor cell similarly treat patient loss heterozygosity chromosome 16q 1p increase DNA content tumor cell . - Determine whether rate complete partial response exceed 20 % patient relapse clear cell sarcoma kidney diffuse anaplastic Wilms ' tumor treat CBDCA combine VP-16 . OUTLINE : This multicenter study . Patients assign treatment group base initial therapy histology . Patients age 2 diagnosis previously treat nephrectomy initial therapy stage I favorable histology Wilms ' tumor weigh less 550 gram assign group A . Patients receive Regimen EE-4A initial therapy Wilms ' tumor assign group B . Patients receive Regimen DD-4A initial therapy Wilms ' tumor assign group C. Patients clear cell sarcoma kidney diffuse anaplastic Wilms ' tumor assign group D. Group A - Treatment determine site relapse presence microscopic gross residual disease attempt resection relapse disease . Children suspect intra-abdominal recurrence undergo exploratory surgery determine site recurrence obtain tissue microscopic examination . Patients stage I disease recurrence treat regimen EE-4A . Patients stage II III disease treat regimen DD-4A . - Regimen EE-4A : Patients receive dactinomycin ( DACT ) IV week 0 , 3 , 6 , 9 , 12 , 15 , 18 vincristine ( VCR ) IV week 1-10 , 12 , 15 , 18 absence disease progression . - Regimen DD-4A : Patients receive DACT IV week 0 , 6 , 12 , 18 , 24 ; VCR IV weekly week 1-10 , 12 , 15 , 18 , 21 , 24 ; doxorubicin ( DOX ) IV week 3 , 9 , 15 , 21 ; abdominal radiotherapy absence disease progression . Group B - Patients undergo resection . After resection , patient receive regimen I comprise DOX IV week 0 , 6 , 12 , 18 , 24 ; VCR IV week 1 , 2 , 4 , 5-8 , 10-13 , 18 , 24 ; cyclophosphamide ( CTX ) IV 1 hour day 1-3 week 6 , 12 , 18 , 24 day 1-5 week 3 , 9 , 15 , 21 ; etoposide ( VP-16 ) IV 1 hour ( CTX infusion ) day 1-5 week 3 , 9 , 15 , 21 absence disease progression . Filgrastim ( G-CSF ) administer subcutaneously ( SC ) begin 24 hour completion chemotherapy continue blood count recover . Patients undergo radiotherapy site recurrence begin within 1 week initiation chemotherapy . Group C - Induction : Patients receive CTX IV 1 hour day 1-5 week 0 3 ; VP-16 IV 1 hour ( CTX infusion ) day 1-5 week 0 3 day 1-3 week 6 9 ; carboplatin ( CBDCA ) IV 6 hour day 1 2 week 6 9 absence disease progression . G-CSF administer SC begin 24 hour completion CTX/VP-16 CBDCA/VP-16 continue blood count recover . - Surgery : Patients detectable disease undergo resection week 13 . If complete resection achieve deem impossible , resection must attempt later 3 week consolidation radiotherapy . - Consolidation : Beginning within 9 day surgery , patient receive CTX IV 1 hour day 1-5 week 1 ; VP-16 IV 1 hour ( CTX infusion ) day 1-5 week 1 day 1-3 week 4 ; CBDCA IV 6 hour day 1 2 week 4 ; G-CSF induction ; radiotherapy absence disease progression . Patients complete partial response resection and/or radiotherapy proceed maintenance therapy . - Maintenance : Patients receive CTX IV 1 hour day 1-5 week 0 3 ; VP-16 IV 1 hour day 1-5 week 0 3 day 1-3 week 6 9 ; CBDCA IV 6 hour day 1 2 week 6 9 ; G-CSF induction . Treatment continue every 12 week 6 course absence disease progression . Group D - Patients receive CBDCA IV 6 hour day 1 2 VP-16 IV 1 hour ( CBDCA infusion ) day 1-3 week 0 3 . Treatment continue weekly 6 course absence disease progression . Patients follow every 3 month 15 month , every 6 month 1 year , annually 3 year . PROJECTED ACCRUAL : Not specify</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Wilms ' tumor Eligible subtypes : Favorable histology Anaplastic histology Clear cell sarcoma kidney Rhabdoid tumor kidney Relapsed disease entry protocol NWTS5 ( NWTSQ9401 ) PATIENT CHARACTERISTICS : Age : 21 original diagnosis Performance status : Not specify Life expectancy : At least 4 week Hematopoietic : Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time normal SGOT SGPT less 2.5 time normal Renal : Creatinine great 1.5 time normal OR Creatinine clearance GFR least 70 mL/min Cardiovascular : Shortening fraction least 27 % echocardiogram OR Ejection fraction great 50 % echocardiogram MUGA scan Other : Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 2 week since prior chemotherapy recover Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No prior therapy relapse Wilms ' tumor Recovered toxic effect prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>clear cell sarcoma kidney</keyword>
	<keyword>rhabdoid tumor kidney</keyword>
</DOC>